Global Polycystic Ovarian Syndrome Treatment Market
Global Polycystic Ovarian Syndrome Treatment Market

Polycystic Ovarian Syndrome Treatment Comprehensive Study by Treatment (Drug Class (Insulin Sensitizing Agent, Oral Contraceptive, Antiandrogens, Anti-Obesity Drugs and Others), Surgery (Ovarian Wedge Resection, Laparoscopic Ovarian Drilling and Other Surgeries)), Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, Online Providers), End-user (Hospitals, Clinics, Ambulatory Surgical Centres, Others), Diagnosis (Pelvic Examination, Blood Tests, Ultrasound) Players and Region - Global Market Outlook to 2026

Polycystic Ovarian Syndrome Treatment Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Feb 2021 Edition 239 Pages 216 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
What is Polycystic Ovarian Syndrome Treatment Market?

According to Centres for Disease Control and Prevention, United States, the polycystic ovarian syndrome is one of the most common causes of female infertility, affecting 6% to 12% (as many as 5 million) of US women of reproductive age. The polycystic ovarian syndrome is a hormonal disorder that affects a woman’s hormone levels common among women of reproductive age. This syndrome can get during their childbearing years, which may affect their ability to have a child. The symptoms involve irregular periods, excess androgen or polycystic ovaries. Many women have polycystic ovarian syndrome but in one study found that 70 percent of women with PCOS hadn’t been diagnosed.

The market study is being classified and major geographies with country level break-up.

Pfizer Inc. (United States), Sanofi SA (France), Abbott Laboratories (United States), Bristol Myers Squibb (United States), Addex Therapeutics Ltd. (Switzerland), Crinetics Pharmaceuticals (United States), EffRx Pharmaceuticals SA (Switzerland), Neurocrine Biosciences (United States), Ferring BV (Switzerland), Johnson and Johnson (United States), Merck KGaA (Germany), Mylan N.V (United States), Novartis International AG (Switzerland), Teva Pharmaceutical Industries Limited (Israel), Bayer AG (Germany) and AstraZeneca PLC (United Kingdom) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are BIOCAD (Russia), Shire PLC (United States), Takeda Pharmaceutical Company Limited (Japan) and AbbVie Inc. (United States).

The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Polycystic Ovarian Syndrome Treatment market throughout the predicted period.

Segment Analysis
Analyst at AMA have segmented the market study of Global Polycystic Ovarian Syndrome Treatment market by Type, Application and Region.

On the basis of geography, the market of Polycystic Ovarian Syndrome Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Geographical Prevalence of Polycystic Ovarian Syndrome among Women
  • Development of New Diagnostic Centres and Hospitals in Developing Countries
  • Increase in Healthcare Expenditure

Market Trend
  • Growing Focus on Preventive Healthcare

Restraints
  • Less Awareness about Polycystic Ovarian Syndrome among Women

Opportunities
  • Development of Healthcare Infrastructure in Emerging Economies
  • Growing Number of Regulatory Approvals
  • Technological Advancements in the field of Medical Science

Challenges
  • Stringent Government Rules and Regulations


In January 2020, Evotec SE and Bayer AG have announced the expansion of their partnership in women’s health indications with a new five-year, multi-target collaboration with participation from Celmatix Inc. to develop multiple clinical candidates for the treatment of polycystic ovary syndrome (“PCOS”).


Key Target Audience
Polycystic Ovarian Syndrome Treatment Providers, Emerging Companies, Research Professionals and End-users

Customization in the Report Available:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Treatment
  • Drug Class (Insulin Sensitizing Agent, Oral Contraceptive, Antiandrogens, Anti-Obesity Drugs and Others)
  • Surgery (Ovarian Wedge Resection, Laparoscopic Ovarian Drilling and Other Surgeries)

By Distribution Channel
  • Hospital Pharmacies
  • Drug Stores & Retail Pharmacies
  • Online Providers

By End-user
  • Hospitals
  • Clinics
  • Ambulatory Surgical Centres
  • Others

By Diagnosis
  • Pelvic Examination
  • Blood Tests
  • Ultrasound

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Geographical Prevalence of Polycystic Ovarian Syndrome among Women
      • 3.2.2. Development of New Diagnostic Centres and Hospitals in Developing Countries
      • 3.2.3. Increase in Healthcare Expenditure
    • 3.3. Market Challenges
      • 3.3.1. Stringent Government Rules and Regulations
    • 3.4. Market Trends
      • 3.4.1. Growing Focus on Preventive Healthcare
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Polycystic Ovarian Syndrome Treatment, by Treatment, Distribution Channel, End-user, Diagnosis and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Polycystic Ovarian Syndrome Treatment (Value)
      • 5.2.1. Global Polycystic Ovarian Syndrome Treatment by: Treatment (Value)
        • 5.2.1.1. Drug Class (Insulin Sensitizing Agent, Oral Contraceptive, Antiandrogens, Anti-Obesity Drugs and Others)
        • 5.2.1.2. Surgery (Ovarian Wedge Resection, Laparoscopic Ovarian Drilling and Other Surgeries)
      • 5.2.2. Global Polycystic Ovarian Syndrome Treatment by: Distribution Channel (Value)
        • 5.2.2.1. Hospital Pharmacies
        • 5.2.2.2. Drug Stores & Retail Pharmacies
        • 5.2.2.3. Online Providers
      • 5.2.3. Global Polycystic Ovarian Syndrome Treatment by: End-user (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Clinics
        • 5.2.3.3. Ambulatory Surgical Centres
        • 5.2.3.4. Others
      • 5.2.4. Global Polycystic Ovarian Syndrome Treatment by: Diagnosis (Value)
        • 5.2.4.1. Pelvic Examination
        • 5.2.4.2. Blood Tests
        • 5.2.4.3. Ultrasound
      • 5.2.5. Global Polycystic Ovarian Syndrome Treatment Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Polycystic Ovarian Syndrome Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Pfizer Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Sanofi SA (France)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Abbott Laboratories (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Bristol Myers Squibb (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Addex Therapeutics Ltd. (Switzerland)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Crinetics Pharmaceuticals (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. EffRx Pharmaceuticals SA (Switzerland)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Neurocrine Biosciences (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Ferring BV (Switzerland)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Johnson and Johnson (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Merck KGaA (Germany)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Mylan N.V (United States)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
      • 6.4.13. Novartis International AG (Switzerland)
        • 6.4.13.1. Business Overview
        • 6.4.13.2. Products/Services Offerings
        • 6.4.13.3. Financial Analysis
        • 6.4.13.4. SWOT Analysis
      • 6.4.14. Teva Pharmaceutical Industries Limited (Israel)
        • 6.4.14.1. Business Overview
        • 6.4.14.2. Products/Services Offerings
        • 6.4.14.3. Financial Analysis
        • 6.4.14.4. SWOT Analysis
      • 6.4.15. Bayer AG (Germany)
        • 6.4.15.1. Business Overview
        • 6.4.15.2. Products/Services Offerings
        • 6.4.15.3. Financial Analysis
        • 6.4.15.4. SWOT Analysis
      • 6.4.16. AstraZeneca PLC (United Kingdom)
        • 6.4.16.1. Business Overview
        • 6.4.16.2. Products/Services Offerings
        • 6.4.16.3. Financial Analysis
        • 6.4.16.4. SWOT Analysis
  • 7. Global Polycystic Ovarian Syndrome Treatment Sale, by Treatment, Distribution Channel, End-user, Diagnosis and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Polycystic Ovarian Syndrome Treatment (Value)
      • 7.2.1. Global Polycystic Ovarian Syndrome Treatment by: Treatment (Value)
        • 7.2.1.1. Drug Class (Insulin Sensitizing Agent, Oral Contraceptive, Antiandrogens, Anti-Obesity Drugs and Others)
        • 7.2.1.2. Surgery (Ovarian Wedge Resection, Laparoscopic Ovarian Drilling and Other Surgeries)
      • 7.2.2. Global Polycystic Ovarian Syndrome Treatment by: Distribution Channel (Value)
        • 7.2.2.1. Hospital Pharmacies
        • 7.2.2.2. Drug Stores & Retail Pharmacies
        • 7.2.2.3. Online Providers
      • 7.2.3. Global Polycystic Ovarian Syndrome Treatment by: End-user (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Clinics
        • 7.2.3.3. Ambulatory Surgical Centres
        • 7.2.3.4. Others
      • 7.2.4. Global Polycystic Ovarian Syndrome Treatment by: Diagnosis (Value)
        • 7.2.4.1. Pelvic Examination
        • 7.2.4.2. Blood Tests
        • 7.2.4.3. Ultrasound
      • 7.2.5. Global Polycystic Ovarian Syndrome Treatment Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Polycystic Ovarian Syndrome Treatment: by Treatment(USD Million)
  • Table 2. Polycystic Ovarian Syndrome Treatment Drug Class (Insulin Sensitizing Agent, Oral Contraceptive, Antiandrogens, Anti-Obesity Drugs and Others) , by Region USD Million (2015-2020)
  • Table 3. Polycystic Ovarian Syndrome Treatment Surgery (Ovarian Wedge Resection, Laparoscopic Ovarian Drilling and Other Surgeries) , by Region USD Million (2015-2020)
  • Table 4. Polycystic Ovarian Syndrome Treatment: by Distribution Channel(USD Million)
  • Table 5. Polycystic Ovarian Syndrome Treatment Hospital Pharmacies , by Region USD Million (2015-2020)
  • Table 6. Polycystic Ovarian Syndrome Treatment Drug Stores & Retail Pharmacies , by Region USD Million (2015-2020)
  • Table 7. Polycystic Ovarian Syndrome Treatment Online Providers , by Region USD Million (2015-2020)
  • Table 8. Polycystic Ovarian Syndrome Treatment: by End-user(USD Million)
  • Table 9. Polycystic Ovarian Syndrome Treatment Hospitals , by Region USD Million (2015-2020)
  • Table 10. Polycystic Ovarian Syndrome Treatment Clinics , by Region USD Million (2015-2020)
  • Table 11. Polycystic Ovarian Syndrome Treatment Ambulatory Surgical Centres , by Region USD Million (2015-2020)
  • Table 12. Polycystic Ovarian Syndrome Treatment Others , by Region USD Million (2015-2020)
  • Table 13. Polycystic Ovarian Syndrome Treatment: by Diagnosis(USD Million)
  • Table 14. Polycystic Ovarian Syndrome Treatment Pelvic Examination , by Region USD Million (2015-2020)
  • Table 15. Polycystic Ovarian Syndrome Treatment Blood Tests , by Region USD Million (2015-2020)
  • Table 16. Polycystic Ovarian Syndrome Treatment Ultrasound , by Region USD Million (2015-2020)
  • Table 17. South America Polycystic Ovarian Syndrome Treatment, by Country USD Million (2015-2020)
  • Table 18. South America Polycystic Ovarian Syndrome Treatment, by Treatment USD Million (2015-2020)
  • Table 19. South America Polycystic Ovarian Syndrome Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 20. South America Polycystic Ovarian Syndrome Treatment, by End-user USD Million (2015-2020)
  • Table 21. South America Polycystic Ovarian Syndrome Treatment, by Diagnosis USD Million (2015-2020)
  • Table 22. Brazil Polycystic Ovarian Syndrome Treatment, by Treatment USD Million (2015-2020)
  • Table 23. Brazil Polycystic Ovarian Syndrome Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 24. Brazil Polycystic Ovarian Syndrome Treatment, by End-user USD Million (2015-2020)
  • Table 25. Brazil Polycystic Ovarian Syndrome Treatment, by Diagnosis USD Million (2015-2020)
  • Table 26. Argentina Polycystic Ovarian Syndrome Treatment, by Treatment USD Million (2015-2020)
  • Table 27. Argentina Polycystic Ovarian Syndrome Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 28. Argentina Polycystic Ovarian Syndrome Treatment, by End-user USD Million (2015-2020)
  • Table 29. Argentina Polycystic Ovarian Syndrome Treatment, by Diagnosis USD Million (2015-2020)
  • Table 30. Rest of South America Polycystic Ovarian Syndrome Treatment, by Treatment USD Million (2015-2020)
  • Table 31. Rest of South America Polycystic Ovarian Syndrome Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 32. Rest of South America Polycystic Ovarian Syndrome Treatment, by End-user USD Million (2015-2020)
  • Table 33. Rest of South America Polycystic Ovarian Syndrome Treatment, by Diagnosis USD Million (2015-2020)
  • Table 34. Asia Pacific Polycystic Ovarian Syndrome Treatment, by Country USD Million (2015-2020)
  • Table 35. Asia Pacific Polycystic Ovarian Syndrome Treatment, by Treatment USD Million (2015-2020)
  • Table 36. Asia Pacific Polycystic Ovarian Syndrome Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 37. Asia Pacific Polycystic Ovarian Syndrome Treatment, by End-user USD Million (2015-2020)
  • Table 38. Asia Pacific Polycystic Ovarian Syndrome Treatment, by Diagnosis USD Million (2015-2020)
  • Table 39. China Polycystic Ovarian Syndrome Treatment, by Treatment USD Million (2015-2020)
  • Table 40. China Polycystic Ovarian Syndrome Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 41. China Polycystic Ovarian Syndrome Treatment, by End-user USD Million (2015-2020)
  • Table 42. China Polycystic Ovarian Syndrome Treatment, by Diagnosis USD Million (2015-2020)
  • Table 43. Japan Polycystic Ovarian Syndrome Treatment, by Treatment USD Million (2015-2020)
  • Table 44. Japan Polycystic Ovarian Syndrome Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 45. Japan Polycystic Ovarian Syndrome Treatment, by End-user USD Million (2015-2020)
  • Table 46. Japan Polycystic Ovarian Syndrome Treatment, by Diagnosis USD Million (2015-2020)
  • Table 47. India Polycystic Ovarian Syndrome Treatment, by Treatment USD Million (2015-2020)
  • Table 48. India Polycystic Ovarian Syndrome Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 49. India Polycystic Ovarian Syndrome Treatment, by End-user USD Million (2015-2020)
  • Table 50. India Polycystic Ovarian Syndrome Treatment, by Diagnosis USD Million (2015-2020)
  • Table 51. South Korea Polycystic Ovarian Syndrome Treatment, by Treatment USD Million (2015-2020)
  • Table 52. South Korea Polycystic Ovarian Syndrome Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 53. South Korea Polycystic Ovarian Syndrome Treatment, by End-user USD Million (2015-2020)
  • Table 54. South Korea Polycystic Ovarian Syndrome Treatment, by Diagnosis USD Million (2015-2020)
  • Table 55. Taiwan Polycystic Ovarian Syndrome Treatment, by Treatment USD Million (2015-2020)
  • Table 56. Taiwan Polycystic Ovarian Syndrome Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 57. Taiwan Polycystic Ovarian Syndrome Treatment, by End-user USD Million (2015-2020)
  • Table 58. Taiwan Polycystic Ovarian Syndrome Treatment, by Diagnosis USD Million (2015-2020)
  • Table 59. Australia Polycystic Ovarian Syndrome Treatment, by Treatment USD Million (2015-2020)
  • Table 60. Australia Polycystic Ovarian Syndrome Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 61. Australia Polycystic Ovarian Syndrome Treatment, by End-user USD Million (2015-2020)
  • Table 62. Australia Polycystic Ovarian Syndrome Treatment, by Diagnosis USD Million (2015-2020)
  • Table 63. Rest of Asia-Pacific Polycystic Ovarian Syndrome Treatment, by Treatment USD Million (2015-2020)
  • Table 64. Rest of Asia-Pacific Polycystic Ovarian Syndrome Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 65. Rest of Asia-Pacific Polycystic Ovarian Syndrome Treatment, by End-user USD Million (2015-2020)
  • Table 66. Rest of Asia-Pacific Polycystic Ovarian Syndrome Treatment, by Diagnosis USD Million (2015-2020)
  • Table 67. Europe Polycystic Ovarian Syndrome Treatment, by Country USD Million (2015-2020)
  • Table 68. Europe Polycystic Ovarian Syndrome Treatment, by Treatment USD Million (2015-2020)
  • Table 69. Europe Polycystic Ovarian Syndrome Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 70. Europe Polycystic Ovarian Syndrome Treatment, by End-user USD Million (2015-2020)
  • Table 71. Europe Polycystic Ovarian Syndrome Treatment, by Diagnosis USD Million (2015-2020)
  • Table 72. Germany Polycystic Ovarian Syndrome Treatment, by Treatment USD Million (2015-2020)
  • Table 73. Germany Polycystic Ovarian Syndrome Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 74. Germany Polycystic Ovarian Syndrome Treatment, by End-user USD Million (2015-2020)
  • Table 75. Germany Polycystic Ovarian Syndrome Treatment, by Diagnosis USD Million (2015-2020)
  • Table 76. France Polycystic Ovarian Syndrome Treatment, by Treatment USD Million (2015-2020)
  • Table 77. France Polycystic Ovarian Syndrome Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 78. France Polycystic Ovarian Syndrome Treatment, by End-user USD Million (2015-2020)
  • Table 79. France Polycystic Ovarian Syndrome Treatment, by Diagnosis USD Million (2015-2020)
  • Table 80. Italy Polycystic Ovarian Syndrome Treatment, by Treatment USD Million (2015-2020)
  • Table 81. Italy Polycystic Ovarian Syndrome Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 82. Italy Polycystic Ovarian Syndrome Treatment, by End-user USD Million (2015-2020)
  • Table 83. Italy Polycystic Ovarian Syndrome Treatment, by Diagnosis USD Million (2015-2020)
  • Table 84. United Kingdom Polycystic Ovarian Syndrome Treatment, by Treatment USD Million (2015-2020)
  • Table 85. United Kingdom Polycystic Ovarian Syndrome Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 86. United Kingdom Polycystic Ovarian Syndrome Treatment, by End-user USD Million (2015-2020)
  • Table 87. United Kingdom Polycystic Ovarian Syndrome Treatment, by Diagnosis USD Million (2015-2020)
  • Table 88. Netherlands Polycystic Ovarian Syndrome Treatment, by Treatment USD Million (2015-2020)
  • Table 89. Netherlands Polycystic Ovarian Syndrome Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 90. Netherlands Polycystic Ovarian Syndrome Treatment, by End-user USD Million (2015-2020)
  • Table 91. Netherlands Polycystic Ovarian Syndrome Treatment, by Diagnosis USD Million (2015-2020)
  • Table 92. Rest of Europe Polycystic Ovarian Syndrome Treatment, by Treatment USD Million (2015-2020)
  • Table 93. Rest of Europe Polycystic Ovarian Syndrome Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 94. Rest of Europe Polycystic Ovarian Syndrome Treatment, by End-user USD Million (2015-2020)
  • Table 95. Rest of Europe Polycystic Ovarian Syndrome Treatment, by Diagnosis USD Million (2015-2020)
  • Table 96. MEA Polycystic Ovarian Syndrome Treatment, by Country USD Million (2015-2020)
  • Table 97. MEA Polycystic Ovarian Syndrome Treatment, by Treatment USD Million (2015-2020)
  • Table 98. MEA Polycystic Ovarian Syndrome Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 99. MEA Polycystic Ovarian Syndrome Treatment, by End-user USD Million (2015-2020)
  • Table 100. MEA Polycystic Ovarian Syndrome Treatment, by Diagnosis USD Million (2015-2020)
  • Table 101. Middle East Polycystic Ovarian Syndrome Treatment, by Treatment USD Million (2015-2020)
  • Table 102. Middle East Polycystic Ovarian Syndrome Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 103. Middle East Polycystic Ovarian Syndrome Treatment, by End-user USD Million (2015-2020)
  • Table 104. Middle East Polycystic Ovarian Syndrome Treatment, by Diagnosis USD Million (2015-2020)
  • Table 105. Africa Polycystic Ovarian Syndrome Treatment, by Treatment USD Million (2015-2020)
  • Table 106. Africa Polycystic Ovarian Syndrome Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 107. Africa Polycystic Ovarian Syndrome Treatment, by End-user USD Million (2015-2020)
  • Table 108. Africa Polycystic Ovarian Syndrome Treatment, by Diagnosis USD Million (2015-2020)
  • Table 109. North America Polycystic Ovarian Syndrome Treatment, by Country USD Million (2015-2020)
  • Table 110. North America Polycystic Ovarian Syndrome Treatment, by Treatment USD Million (2015-2020)
  • Table 111. North America Polycystic Ovarian Syndrome Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 112. North America Polycystic Ovarian Syndrome Treatment, by End-user USD Million (2015-2020)
  • Table 113. North America Polycystic Ovarian Syndrome Treatment, by Diagnosis USD Million (2015-2020)
  • Table 114. United States Polycystic Ovarian Syndrome Treatment, by Treatment USD Million (2015-2020)
  • Table 115. United States Polycystic Ovarian Syndrome Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 116. United States Polycystic Ovarian Syndrome Treatment, by End-user USD Million (2015-2020)
  • Table 117. United States Polycystic Ovarian Syndrome Treatment, by Diagnosis USD Million (2015-2020)
  • Table 118. Canada Polycystic Ovarian Syndrome Treatment, by Treatment USD Million (2015-2020)
  • Table 119. Canada Polycystic Ovarian Syndrome Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 120. Canada Polycystic Ovarian Syndrome Treatment, by End-user USD Million (2015-2020)
  • Table 121. Canada Polycystic Ovarian Syndrome Treatment, by Diagnosis USD Million (2015-2020)
  • Table 122. Mexico Polycystic Ovarian Syndrome Treatment, by Treatment USD Million (2015-2020)
  • Table 123. Mexico Polycystic Ovarian Syndrome Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 124. Mexico Polycystic Ovarian Syndrome Treatment, by End-user USD Million (2015-2020)
  • Table 125. Mexico Polycystic Ovarian Syndrome Treatment, by Diagnosis USD Million (2015-2020)
  • Table 126. Company Basic Information, Sales Area and Its Competitors
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Company Basic Information, Sales Area and Its Competitors
  • Table 141. Company Basic Information, Sales Area and Its Competitors
  • Table 142. Polycystic Ovarian Syndrome Treatment: by Treatment(USD Million)
  • Table 143. Polycystic Ovarian Syndrome Treatment Drug Class (Insulin Sensitizing Agent, Oral Contraceptive, Antiandrogens, Anti-Obesity Drugs and Others) , by Region USD Million (2021-2026)
  • Table 144. Polycystic Ovarian Syndrome Treatment Surgery (Ovarian Wedge Resection, Laparoscopic Ovarian Drilling and Other Surgeries) , by Region USD Million (2021-2026)
  • Table 145. Polycystic Ovarian Syndrome Treatment: by Distribution Channel(USD Million)
  • Table 146. Polycystic Ovarian Syndrome Treatment Hospital Pharmacies , by Region USD Million (2021-2026)
  • Table 147. Polycystic Ovarian Syndrome Treatment Drug Stores & Retail Pharmacies , by Region USD Million (2021-2026)
  • Table 148. Polycystic Ovarian Syndrome Treatment Online Providers , by Region USD Million (2021-2026)
  • Table 149. Polycystic Ovarian Syndrome Treatment: by End-user(USD Million)
  • Table 150. Polycystic Ovarian Syndrome Treatment Hospitals , by Region USD Million (2021-2026)
  • Table 151. Polycystic Ovarian Syndrome Treatment Clinics , by Region USD Million (2021-2026)
  • Table 152. Polycystic Ovarian Syndrome Treatment Ambulatory Surgical Centres , by Region USD Million (2021-2026)
  • Table 153. Polycystic Ovarian Syndrome Treatment Others , by Region USD Million (2021-2026)
  • Table 154. Polycystic Ovarian Syndrome Treatment: by Diagnosis(USD Million)
  • Table 155. Polycystic Ovarian Syndrome Treatment Pelvic Examination , by Region USD Million (2021-2026)
  • Table 156. Polycystic Ovarian Syndrome Treatment Blood Tests , by Region USD Million (2021-2026)
  • Table 157. Polycystic Ovarian Syndrome Treatment Ultrasound , by Region USD Million (2021-2026)
  • Table 158. South America Polycystic Ovarian Syndrome Treatment, by Country USD Million (2021-2026)
  • Table 159. South America Polycystic Ovarian Syndrome Treatment, by Treatment USD Million (2021-2026)
  • Table 160. South America Polycystic Ovarian Syndrome Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 161. South America Polycystic Ovarian Syndrome Treatment, by End-user USD Million (2021-2026)
  • Table 162. South America Polycystic Ovarian Syndrome Treatment, by Diagnosis USD Million (2021-2026)
  • Table 163. Brazil Polycystic Ovarian Syndrome Treatment, by Treatment USD Million (2021-2026)
  • Table 164. Brazil Polycystic Ovarian Syndrome Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 165. Brazil Polycystic Ovarian Syndrome Treatment, by End-user USD Million (2021-2026)
  • Table 166. Brazil Polycystic Ovarian Syndrome Treatment, by Diagnosis USD Million (2021-2026)
  • Table 167. Argentina Polycystic Ovarian Syndrome Treatment, by Treatment USD Million (2021-2026)
  • Table 168. Argentina Polycystic Ovarian Syndrome Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 169. Argentina Polycystic Ovarian Syndrome Treatment, by End-user USD Million (2021-2026)
  • Table 170. Argentina Polycystic Ovarian Syndrome Treatment, by Diagnosis USD Million (2021-2026)
  • Table 171. Rest of South America Polycystic Ovarian Syndrome Treatment, by Treatment USD Million (2021-2026)
  • Table 172. Rest of South America Polycystic Ovarian Syndrome Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 173. Rest of South America Polycystic Ovarian Syndrome Treatment, by End-user USD Million (2021-2026)
  • Table 174. Rest of South America Polycystic Ovarian Syndrome Treatment, by Diagnosis USD Million (2021-2026)
  • Table 175. Asia Pacific Polycystic Ovarian Syndrome Treatment, by Country USD Million (2021-2026)
  • Table 176. Asia Pacific Polycystic Ovarian Syndrome Treatment, by Treatment USD Million (2021-2026)
  • Table 177. Asia Pacific Polycystic Ovarian Syndrome Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 178. Asia Pacific Polycystic Ovarian Syndrome Treatment, by End-user USD Million (2021-2026)
  • Table 179. Asia Pacific Polycystic Ovarian Syndrome Treatment, by Diagnosis USD Million (2021-2026)
  • Table 180. China Polycystic Ovarian Syndrome Treatment, by Treatment USD Million (2021-2026)
  • Table 181. China Polycystic Ovarian Syndrome Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 182. China Polycystic Ovarian Syndrome Treatment, by End-user USD Million (2021-2026)
  • Table 183. China Polycystic Ovarian Syndrome Treatment, by Diagnosis USD Million (2021-2026)
  • Table 184. Japan Polycystic Ovarian Syndrome Treatment, by Treatment USD Million (2021-2026)
  • Table 185. Japan Polycystic Ovarian Syndrome Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 186. Japan Polycystic Ovarian Syndrome Treatment, by End-user USD Million (2021-2026)
  • Table 187. Japan Polycystic Ovarian Syndrome Treatment, by Diagnosis USD Million (2021-2026)
  • Table 188. India Polycystic Ovarian Syndrome Treatment, by Treatment USD Million (2021-2026)
  • Table 189. India Polycystic Ovarian Syndrome Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 190. India Polycystic Ovarian Syndrome Treatment, by End-user USD Million (2021-2026)
  • Table 191. India Polycystic Ovarian Syndrome Treatment, by Diagnosis USD Million (2021-2026)
  • Table 192. South Korea Polycystic Ovarian Syndrome Treatment, by Treatment USD Million (2021-2026)
  • Table 193. South Korea Polycystic Ovarian Syndrome Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 194. South Korea Polycystic Ovarian Syndrome Treatment, by End-user USD Million (2021-2026)
  • Table 195. South Korea Polycystic Ovarian Syndrome Treatment, by Diagnosis USD Million (2021-2026)
  • Table 196. Taiwan Polycystic Ovarian Syndrome Treatment, by Treatment USD Million (2021-2026)
  • Table 197. Taiwan Polycystic Ovarian Syndrome Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 198. Taiwan Polycystic Ovarian Syndrome Treatment, by End-user USD Million (2021-2026)
  • Table 199. Taiwan Polycystic Ovarian Syndrome Treatment, by Diagnosis USD Million (2021-2026)
  • Table 200. Australia Polycystic Ovarian Syndrome Treatment, by Treatment USD Million (2021-2026)
  • Table 201. Australia Polycystic Ovarian Syndrome Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 202. Australia Polycystic Ovarian Syndrome Treatment, by End-user USD Million (2021-2026)
  • Table 203. Australia Polycystic Ovarian Syndrome Treatment, by Diagnosis USD Million (2021-2026)
  • Table 204. Rest of Asia-Pacific Polycystic Ovarian Syndrome Treatment, by Treatment USD Million (2021-2026)
  • Table 205. Rest of Asia-Pacific Polycystic Ovarian Syndrome Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 206. Rest of Asia-Pacific Polycystic Ovarian Syndrome Treatment, by End-user USD Million (2021-2026)
  • Table 207. Rest of Asia-Pacific Polycystic Ovarian Syndrome Treatment, by Diagnosis USD Million (2021-2026)
  • Table 208. Europe Polycystic Ovarian Syndrome Treatment, by Country USD Million (2021-2026)
  • Table 209. Europe Polycystic Ovarian Syndrome Treatment, by Treatment USD Million (2021-2026)
  • Table 210. Europe Polycystic Ovarian Syndrome Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 211. Europe Polycystic Ovarian Syndrome Treatment, by End-user USD Million (2021-2026)
  • Table 212. Europe Polycystic Ovarian Syndrome Treatment, by Diagnosis USD Million (2021-2026)
  • Table 213. Germany Polycystic Ovarian Syndrome Treatment, by Treatment USD Million (2021-2026)
  • Table 214. Germany Polycystic Ovarian Syndrome Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 215. Germany Polycystic Ovarian Syndrome Treatment, by End-user USD Million (2021-2026)
  • Table 216. Germany Polycystic Ovarian Syndrome Treatment, by Diagnosis USD Million (2021-2026)
  • Table 217. France Polycystic Ovarian Syndrome Treatment, by Treatment USD Million (2021-2026)
  • Table 218. France Polycystic Ovarian Syndrome Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 219. France Polycystic Ovarian Syndrome Treatment, by End-user USD Million (2021-2026)
  • Table 220. France Polycystic Ovarian Syndrome Treatment, by Diagnosis USD Million (2021-2026)
  • Table 221. Italy Polycystic Ovarian Syndrome Treatment, by Treatment USD Million (2021-2026)
  • Table 222. Italy Polycystic Ovarian Syndrome Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 223. Italy Polycystic Ovarian Syndrome Treatment, by End-user USD Million (2021-2026)
  • Table 224. Italy Polycystic Ovarian Syndrome Treatment, by Diagnosis USD Million (2021-2026)
  • Table 225. United Kingdom Polycystic Ovarian Syndrome Treatment, by Treatment USD Million (2021-2026)
  • Table 226. United Kingdom Polycystic Ovarian Syndrome Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 227. United Kingdom Polycystic Ovarian Syndrome Treatment, by End-user USD Million (2021-2026)
  • Table 228. United Kingdom Polycystic Ovarian Syndrome Treatment, by Diagnosis USD Million (2021-2026)
  • Table 229. Netherlands Polycystic Ovarian Syndrome Treatment, by Treatment USD Million (2021-2026)
  • Table 230. Netherlands Polycystic Ovarian Syndrome Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 231. Netherlands Polycystic Ovarian Syndrome Treatment, by End-user USD Million (2021-2026)
  • Table 232. Netherlands Polycystic Ovarian Syndrome Treatment, by Diagnosis USD Million (2021-2026)
  • Table 233. Rest of Europe Polycystic Ovarian Syndrome Treatment, by Treatment USD Million (2021-2026)
  • Table 234. Rest of Europe Polycystic Ovarian Syndrome Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 235. Rest of Europe Polycystic Ovarian Syndrome Treatment, by End-user USD Million (2021-2026)
  • Table 236. Rest of Europe Polycystic Ovarian Syndrome Treatment, by Diagnosis USD Million (2021-2026)
  • Table 237. MEA Polycystic Ovarian Syndrome Treatment, by Country USD Million (2021-2026)
  • Table 238. MEA Polycystic Ovarian Syndrome Treatment, by Treatment USD Million (2021-2026)
  • Table 239. MEA Polycystic Ovarian Syndrome Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 240. MEA Polycystic Ovarian Syndrome Treatment, by End-user USD Million (2021-2026)
  • Table 241. MEA Polycystic Ovarian Syndrome Treatment, by Diagnosis USD Million (2021-2026)
  • Table 242. Middle East Polycystic Ovarian Syndrome Treatment, by Treatment USD Million (2021-2026)
  • Table 243. Middle East Polycystic Ovarian Syndrome Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 244. Middle East Polycystic Ovarian Syndrome Treatment, by End-user USD Million (2021-2026)
  • Table 245. Middle East Polycystic Ovarian Syndrome Treatment, by Diagnosis USD Million (2021-2026)
  • Table 246. Africa Polycystic Ovarian Syndrome Treatment, by Treatment USD Million (2021-2026)
  • Table 247. Africa Polycystic Ovarian Syndrome Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 248. Africa Polycystic Ovarian Syndrome Treatment, by End-user USD Million (2021-2026)
  • Table 249. Africa Polycystic Ovarian Syndrome Treatment, by Diagnosis USD Million (2021-2026)
  • Table 250. North America Polycystic Ovarian Syndrome Treatment, by Country USD Million (2021-2026)
  • Table 251. North America Polycystic Ovarian Syndrome Treatment, by Treatment USD Million (2021-2026)
  • Table 252. North America Polycystic Ovarian Syndrome Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 253. North America Polycystic Ovarian Syndrome Treatment, by End-user USD Million (2021-2026)
  • Table 254. North America Polycystic Ovarian Syndrome Treatment, by Diagnosis USD Million (2021-2026)
  • Table 255. United States Polycystic Ovarian Syndrome Treatment, by Treatment USD Million (2021-2026)
  • Table 256. United States Polycystic Ovarian Syndrome Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 257. United States Polycystic Ovarian Syndrome Treatment, by End-user USD Million (2021-2026)
  • Table 258. United States Polycystic Ovarian Syndrome Treatment, by Diagnosis USD Million (2021-2026)
  • Table 259. Canada Polycystic Ovarian Syndrome Treatment, by Treatment USD Million (2021-2026)
  • Table 260. Canada Polycystic Ovarian Syndrome Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 261. Canada Polycystic Ovarian Syndrome Treatment, by End-user USD Million (2021-2026)
  • Table 262. Canada Polycystic Ovarian Syndrome Treatment, by Diagnosis USD Million (2021-2026)
  • Table 263. Mexico Polycystic Ovarian Syndrome Treatment, by Treatment USD Million (2021-2026)
  • Table 264. Mexico Polycystic Ovarian Syndrome Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 265. Mexico Polycystic Ovarian Syndrome Treatment, by End-user USD Million (2021-2026)
  • Table 266. Mexico Polycystic Ovarian Syndrome Treatment, by Diagnosis USD Million (2021-2026)
  • Table 267. Research Programs/Design for This Report
  • Table 268. Key Data Information from Secondary Sources
  • Table 269. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Polycystic Ovarian Syndrome Treatment: by Treatment USD Million (2015-2020)
  • Figure 5. Global Polycystic Ovarian Syndrome Treatment: by Distribution Channel USD Million (2015-2020)
  • Figure 6. Global Polycystic Ovarian Syndrome Treatment: by End-user USD Million (2015-2020)
  • Figure 7. Global Polycystic Ovarian Syndrome Treatment: by Diagnosis USD Million (2015-2020)
  • Figure 8. South America Polycystic Ovarian Syndrome Treatment Share (%), by Country
  • Figure 9. Asia Pacific Polycystic Ovarian Syndrome Treatment Share (%), by Country
  • Figure 10. Europe Polycystic Ovarian Syndrome Treatment Share (%), by Country
  • Figure 11. MEA Polycystic Ovarian Syndrome Treatment Share (%), by Country
  • Figure 12. North America Polycystic Ovarian Syndrome Treatment Share (%), by Country
  • Figure 13. Global Polycystic Ovarian Syndrome Treatment share by Players 2020 (%)
  • Figure 14. Global Polycystic Ovarian Syndrome Treatment share by Players (Top 3) 2020(%)
  • Figure 15. Global Polycystic Ovarian Syndrome Treatment share by Players (Top 5) 2020(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 18. Pfizer Inc. (United States) Revenue: by Geography 2020
  • Figure 19. Sanofi SA (France) Revenue, Net Income and Gross profit
  • Figure 20. Sanofi SA (France) Revenue: by Geography 2020
  • Figure 21. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 22. Abbott Laboratories (United States) Revenue: by Geography 2020
  • Figure 23. Bristol Myers Squibb (United States) Revenue, Net Income and Gross profit
  • Figure 24. Bristol Myers Squibb (United States) Revenue: by Geography 2020
  • Figure 25. Addex Therapeutics Ltd. (Switzerland) Revenue, Net Income and Gross profit
  • Figure 26. Addex Therapeutics Ltd. (Switzerland) Revenue: by Geography 2020
  • Figure 27. Crinetics Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 28. Crinetics Pharmaceuticals (United States) Revenue: by Geography 2020
  • Figure 29. EffRx Pharmaceuticals SA (Switzerland) Revenue, Net Income and Gross profit
  • Figure 30. EffRx Pharmaceuticals SA (Switzerland) Revenue: by Geography 2020
  • Figure 31. Neurocrine Biosciences (United States) Revenue, Net Income and Gross profit
  • Figure 32. Neurocrine Biosciences (United States) Revenue: by Geography 2020
  • Figure 33. Ferring BV (Switzerland) Revenue, Net Income and Gross profit
  • Figure 34. Ferring BV (Switzerland) Revenue: by Geography 2020
  • Figure 35. Johnson and Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 36. Johnson and Johnson (United States) Revenue: by Geography 2020
  • Figure 37. Merck KGaA (Germany) Revenue, Net Income and Gross profit
  • Figure 38. Merck KGaA (Germany) Revenue: by Geography 2020
  • Figure 39. Mylan N.V (United States) Revenue, Net Income and Gross profit
  • Figure 40. Mylan N.V (United States) Revenue: by Geography 2020
  • Figure 41. Novartis International AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 42. Novartis International AG (Switzerland) Revenue: by Geography 2020
  • Figure 43. Teva Pharmaceutical Industries Limited (Israel) Revenue, Net Income and Gross profit
  • Figure 44. Teva Pharmaceutical Industries Limited (Israel) Revenue: by Geography 2020
  • Figure 45. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 46. Bayer AG (Germany) Revenue: by Geography 2020
  • Figure 47. AstraZeneca PLC (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 48. AstraZeneca PLC (United Kingdom) Revenue: by Geography 2020
  • Figure 49. Global Polycystic Ovarian Syndrome Treatment: by Treatment USD Million (2021-2026)
  • Figure 50. Global Polycystic Ovarian Syndrome Treatment: by Distribution Channel USD Million (2021-2026)
  • Figure 51. Global Polycystic Ovarian Syndrome Treatment: by End-user USD Million (2021-2026)
  • Figure 52. Global Polycystic Ovarian Syndrome Treatment: by Diagnosis USD Million (2021-2026)
  • Figure 53. South America Polycystic Ovarian Syndrome Treatment Share (%), by Country
  • Figure 54. Asia Pacific Polycystic Ovarian Syndrome Treatment Share (%), by Country
  • Figure 55. Europe Polycystic Ovarian Syndrome Treatment Share (%), by Country
  • Figure 56. MEA Polycystic Ovarian Syndrome Treatment Share (%), by Country
  • Figure 57. North America Polycystic Ovarian Syndrome Treatment Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Pfizer Inc. (United States)
  • Sanofi SA (France)
  • Abbott Laboratories (United States)
  • Bristol Myers Squibb (United States)
  • Addex Therapeutics Ltd. (Switzerland)
  • Crinetics Pharmaceuticals (United States)
  • EffRx Pharmaceuticals SA (Switzerland)
  • Neurocrine Biosciences (United States)
  • Ferring BV (Switzerland)
  • Johnson and Johnson (United States)
  • Merck KGaA (Germany)
  • Mylan N.V (United States)
  • Novartis International AG (Switzerland)
  • Teva Pharmaceutical Industries Limited (Israel)
  • Bayer AG (Germany)
  • AstraZeneca PLC (United Kingdom)
Additional players considered in the study are as follows:
BIOCAD (Russia) , Shire PLC (United States) , Takeda Pharmaceutical Company Limited (Japan) , AbbVie Inc. (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation